Free Trial

Voyager Therapeutics (VYGR) Competitors

Voyager Therapeutics logo
$2.92 -0.08 (-2.51%)
As of 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VYGR vs. NAGE, VIR, AVXL, NUVB, QURE, IMNM, AVBP, TRVI, PHAR, and DAWN

Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Niagen Bioscience (NAGE), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), uniQure (QURE), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry.

Voyager Therapeutics vs.

Voyager Therapeutics (NASDAQ:VYGR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Voyager Therapeutics has higher earnings, but lower revenue than Niagen Bioscience. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$66.96M2.43$132.33M-$1.46-2.01
Niagen Bioscience$107.93M7.26$13.39M$0.1758.53

Voyager Therapeutics received 401 more outperform votes than Niagen Bioscience when rated by MarketBeat users.

CompanyUnderperformOutperform
Voyager TherapeuticsOutperform Votes
401
67.97%
Underperform Votes
189
32.03%
Niagen BioscienceN/AN/A

Voyager Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500.

In the previous week, Voyager Therapeutics had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Voyager Therapeutics and 1 mentions for Niagen Bioscience. Voyager Therapeutics' average media sentiment score of 0.74 beat Niagen Bioscience's score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Voyager Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Niagen Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Voyager Therapeutics currently has a consensus target price of $13.39, indicating a potential upside of 355.44%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Voyager Therapeutics is more favorable than Niagen Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Niagen Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Voyager Therapeutics has a net margin of 15.80% compared to Niagen Bioscience's net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Niagen Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics15.80% 8.33% 6.15%
Niagen Bioscience N/A N/A N/A

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Voyager Therapeutics beats Niagen Bioscience on 12 of the 18 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYGR vs. The Competition

MetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$162.69M$2.91B$5.31B$8.28B
Dividend YieldN/A1.63%5.20%4.10%
P/E Ratio4.1430.8726.7319.58
Price / Sales2.43396.15387.44119.65
Price / Cash1.41168.6838.2534.62
Price / Book0.553.206.744.47
Net Income$132.33M-$72.35M$3.23B$248.22M
7 Day Performance-10.91%1.45%-0.05%-1.32%
1 Month Performance-15.76%1.52%8.51%10.73%
1 Year Performance-63.70%-25.72%18.25%8.40%

Voyager Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYGR
Voyager Therapeutics
4.6574 of 5 stars
$2.92
-2.5%
$13.39
+359.3%
-64.0%$161.30M$66.96M4.11100Gap Down
NAGE
Niagen Bioscience
N/A$9.39
+4.9%
N/AN/A$738.84M$99.60M55.24120News Coverage
Gap Down
VIR
Vir Biotechnology
2.9115 of 5 stars
$5.30
+4.1%
$32.86
+519.9%
-59.5%$731.74M$14.30M-1.35580News Coverage
Positive News
Analyst Forecast
Analyst Revision
Gap Down
AVXL
Anavex Life Sciences
3.8508 of 5 stars
$8.55
+3.6%
$44.00
+414.6%
+70.4%$729.93MN/A-15.5540
NUVB
Nuvation Bio
3.6947 of 5 stars
$2.15
+2.6%
$7.83
+265.2%
-31.6%$726.47M$7.87M-0.9960Positive News
Gap Up
QURE
uniQure
2.9676 of 5 stars
$13.15
+2.8%
$37.82
+187.6%
+202.2%$720.30M$27.12M-2.65500Options Volume
Analyst Revision
IMNM
Immunome
2.6297 of 5 stars
$7.94
+6.4%
$25.33
+219.1%
-41.3%$690.88M$9.04M-0.9840Positive News
Analyst Upgrade
AVBP
ArriVent BioPharma
0.9907 of 5 stars
$19.99
-0.8%
$39.00
+95.1%
+3.7%$680.56MN/A-7.7840Analyst Forecast
TRVI
Trevi Therapeutics
3.4715 of 5 stars
$6.70
+1.5%
$17.56
+162.1%
+127.5%$669.28MN/A-15.2320News Coverage
Positive News
Analyst Forecast
PHAR
Pharming Group
1.7822 of 5 stars
$9.81
-2.2%
$30.00
+206.0%
+13.3%$667.04M$297.20M-37.71280Gap Up
DAWN
Day One Biopharmaceuticals
2.7422 of 5 stars
$6.58
+2.0%
$30.57
+364.6%
-57.1%$666.96M$161.92M-6.3960

Related Companies and Tools


This page (NASDAQ:VYGR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners